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Abstract 
Proteins have a natural tendency to convert from their native forms into insoluble aggregates and 
this phenomenon give rise to a number of human diseases including Alzheimer and Parkinson 
diseases, type II diabetes and amyloidosis. We will describe complete lists of proteins forming 
amyloid and other type of protein deposits in human pathology and the disorders associated with 
their deposition, as well as the proteins that exploit the amyloid motif to play specific functional 
roles in humans. We will then describe the genetics associated with such diseases with the aim of 
learning the critical steps of the pathogenesis with amyloid aggregation. We describe recent 
advances in our understanding of the structure of amyloid fibrils and their precursor oligomers, as 
well as mechanisms of their formation and ability to cause cell dysfunction. Finally we will present 
evidence that a complex proteostasis network actively combats proteins aggregation and the reasons 
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Just over ten years ago we wrote an article for Annual Reviews of Biochemistry entitled ‘Protein 
Misfolding, Functional Amyloid and Human Disease’ (1). In the Introduction to this article we 
noted that “writing a review on protein aggregation and its associated diseases is a challenging 
activity, due to the astonishingly high number of papers published on this broad topic and the 
heterogeneity of the clinical profiles of the diseases and of the proteins associated with them”. This 
task might now be seen to be even more challenging as the number of papers per year with 
‘amyloid’ in the title or abstract has increased by a factor of two over that time. On the other hand, 
huge progress has been made in understanding the process of amyloid formation and its 
significance in the normal and aberrant behaviour of biological systems. In particular, the 
development and application of new experimental and theoretical methodologies and the 
availability of a wealth of experimental data from various disciplines has transformed our 
knowledge of this increasingly important field of science. 
As in our previous review we have looked in particular across the various manifestations of 
the ‘amyloid phenomenon’ to identify and describe its common or ‘generic’ features, from a 
physicochemical, biochemical, genetic and biological angle, with particular emphasis on those 
observations and principles emerging from the study of multiple protein and disease systems. The 
human disorders associated with amyloid formation range from Alzheimer’s disease, in which such 
aggregates are located in the brain, to Type II diabetes, where deposits form in the pancreas, to 
systemic conditions in which deposits can be found in multiple organs, including the liver and the 
heart. In addition, some twenty years ago it became evident that it is possible to find conditions 
under which peptides and proteins with no connection with disease can convert in vitro into fibrils 
with all the characteristics of those associated with amyloid disorders (2, 3). Since polypeptides 
containing only a single type of amino acid residue, such as polylysine and polythreonine, and even 
single amino acid residues, such as L-phenylalanine, can form such fibrils (4, 5), this finding added 
strong support to the suggestion that the ability to form this type of structure is an inherent property 
of polypeptide chains rather than being encoded in their sequences, as is the case for the structures 
of the functional states of proteins (1). Indeed, subsequent studies revealed that amyloid fibrils have 
properties that have potential significance for the development of novel biopolymers and 
biomolecular devices (6, 7), and that a number of amyloid fibrils forming naturally under non-
pathological conditions have functional roles in living systems (8-10). 
Our aim in this article is to summarise briefly the information that has been covered in the 
previous review, and that still represents the key fundamental aspects of the amyloid phenomenon, 
and then to place particular emphasis on those areas in which major new advances have been made 
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since it was written. In looking to the future we outline the increasing progress that is being made 
towards the rational development of new therapeutic strategies to combat amyloid-related disorders. 
The importance of the latter topic is that no cures currently exist for any of this family of diseases 
that are increasingly prevalent, in particular because of their links to ageing, most dramatically 
illustrated through Alzheimer’s disease, and to other characteristics of the modern world, such as 
Type II diabetes. Given the enormous burden that these diseases inflict on society and on health 
care budgets the failure to find effective therapies will have a huge impact on human society within 
the next generation. The ultimate aim of this review, therefore, is to summarise the fundamental 
aspects of amyloid fibril formation and its links to human disease, and hence to outline general 
principles through which, we believe, the rational development of therapeutic strategies to combat 
this family of diseases will increasingly achieve success. 
 
STRUCTURAL PLASTICITY OF PROTEINS 
 
In our last review we stressed the fact that a protein molecule can adopt a multitude of different 
conformational states between its synthesis on the ribosome and its eventual degradation through 
proteolysis, with such states interconverting on a wide range of timescales (1). Figure 1 summarises 
a selection of the most important of these different states from a mechanistic and biological 
perspective. A range of proteins, including -synuclein, tau and the islet amyloid polypeptide that 
are of particular interest in the context of protein deposition disorders, remain persistently as 
‘natively unfolded’ or ‘intrinsically disordered’ (Figure 1, box 1), although many such proteins are 
thought to fold into more well-defined structures after interaction with specific binding partners 
(11). Intrinsically disordered systems can also be generated following proteolysis from proteins that 
are otherwise folded, such as the amyloid  peptide and the islet amyloid polypeptide and the 
amyloidogenic fragment of gelsolin (Figure 1, box 1). Most newly synthesized polypeptide chains, 
however, fold through the formation of one or more partially folded states, including lysozyme, 
transthyretin and 2-microglobulin (Figure 1, box 2). Although the classical picture of a natively 
folded protein is that of a highly constrained conformational ensemble, it is clear that many such 
proteins can include significantly disordered regions, of which the mammalian prion protein is a 
clear example. 
The different conformational states adopted by proteins involve a highly complex series of 
equilibria whose thermodynamics and kinetics are determined in a normally functioning living 
system by their own amino acid sequences as well as molecular chaperones, degradation processes 
and other sophisticated quality control mechanisms. Although their amino acid sequences and the 
biological environment in which they function have co-evolved to maintain proteins in their soluble 
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states, in some circumstances they can convert into non-functional and potentially damaging protein 
aggregates (Figure 1, box 3). Protein aggregation has been found to involve both intrinsically 
disordered proteins, such as -synuclein and the amyloid  peptide (12, 13) and globular proteins, 
such as 2-microglobulin and transthyretin (14, 15) (Figure 1, box 3). 
The aggregates that form initially involve a relatively small number of molecules and 
generally retain a structural memory of the monomeric states that have generated them, thus giving 
rise to highly disordered, partially structured and native-like oligomers if they originate from 
unfolded, partially folded and folded monomeric states, respectively (Figure 1, box 3) (12, 13, 16-
22). These early aggregates are typically rather unstable, as only relatively weak intermolecular 
interactions are involved, and may simply dissociate to regenerate soluble species. When 
aggregation proceeds, however, they undergo internal reorganisation to form more stable species 
having -sheet structure, a process that is often accompanied by an increase in compactness and 
size (Figure 1, box 3) (12, 13, 16-22). These -structured oligomers are able to grow further by self-
association or through the addition of monomers, often with further and sometimes dramatic 
structural reorganisations, to form well defined fibrils with cross- structure and a high level of 
structural order (Figure 1, box 4). Alternatively, the disordered aggregates or native-like aggregates 
can grow without conversion into -structured species and give rise to large amorphous deposits or 
native-like assemblies, retaining the structure characterising the initial oligomers (Figure 1, box 4). 
The formation of all of such large aggregates, including amyloid, amorphous or native-like 
assemblies, has a link with human disease as they accumulate in well defined pathological states. 
Table 1 and Table 2 list the proteins and disorders that have now been identified as linked to the 
formation of amyloid fibrils or other types of aggregates, respectively. We have structured both 
tables in terms of proteins rather than disorders to stress the fact that many of these proteins are 
found to be involved in a variety of pathological conditions. Interestingly, immunoglobulins or their 
subunits are found in all the different types of of protein aggregates, including amyloid (as in light 
chain amyloidosis), amorphous (as in light chain deposition disease) and native-like (as in Berger 
disease), thus representing a remarkable manifestation of the multiplicity of pathways existing in 
protein aggregation and of structures/morphologies that can be generated (23, 24, 25). 
We also list in Table 3 examples where amyloid structures have been found to have 
functional significance in humans. These forms of ‘functional amyloid’ appear to be largely found 
in bacterial and fungal systems but several interesting examples have been detected in higher 
organisms including humans (8-10, 26). Since most of the protein deposits associated with protein 
misfolding diseases consist of amyloid fibrils, in the remainder of this article we shall focus on 
amyloid structures and their significance in disease, with the major emphasis on the substantial 
progress in this area that has been made over the past decade. 
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THE MOLECULAR NATURE OF AMYLOID-RELATED DISEASES 
 
General overview 
35 peptides/proteins have so far been found to form amyloid deposits in human pathologies (Table 
1, column 1). Most of these systems are secreted, and the resulting deposits are found to be in 
extracellular space. Indeed, only four of the proteins listed in Table 1 (labelled with the superscript 
e) are cytosolic and form intracellular inclusions with amyloid-like characteristics. In addition, most 
of the polyeptides involved are small in size: half of them have less than 100 amino acid residues, 
only four have more than 400 residues and none has more than 700 residues (Table 1, column 2). 
By comparison, the average length of the ca. 34,180 proteins encoded in the human genome is 
almost 500 residues (27). Thirteen of the known amyloid-associated proteins adopt a well-defined 
fold in their native states with a variety of secondary, tertiary, and sometimes quaternary structural 
characteristics; twelve are intrinsically disordered, often consisting of fragments generated from 
larger proteins by proteolytic cleavage; nine are of unknown structure and one contains both a 
globular and an intrinsically disordered domain (Table 1, column 3). There are no significant or 
even detectable similarities between the proteins in sequence, structure or function. 
Seven of the proteins associated with disease form amyloid deposits in the central nervous 
system, giving rise to neurodegenerative conditions, such as Alzheimer’s and Parkinson’s disease, 
whilst the remainder form deposits in other tissues and the resulting diseases are thus non-
neuropathic (Table 1, columns 4-5). In this latter group of 27 proteins, 13 aggregate in a range of 
tissues, including the heart, spleen, liver and kidney, and give rise to systemic amyloidosis, whereas 
15 aggregate in one of a variety of specific tissue, giving rise to a diverse range of conditions 
including, for example, type II diabetes and atrial amyloidosis (Table 1, columns 4-5). The ABri 
peptide, associated with Familial British dementia, has a significant overlap with both groups of 
neuropathic and non-neuropathic diseases, as it forms deposits in both the brain and in other tissues 
(28). TTR is also an unusual case as the associated diseases are generally systemic or involve the 
peripheral nervous system or the heart; however, a small number of mutations of this protein also 
give rise to a leptomeningeal (or central nervous system) amyloidosis affecting the brain (15). 
One third of the diseases are always familial, and in such situations generally have an early 
age of onset (Table 1, column 5). The mutations are generally located in the sequence of the 
polypeptide chain that undergoes aggregation and are autosomal dominant, i.e. a mutation in just 
one copy of the gene is sufficient to cause disease. In some of these hereditary diseases the cause-
effect relationship of the mutation(s) has been studied in detail, clarifying the mechanism of action 
through which the mutations are aggregation-prone and pathogenic (see section below). Half of the 
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amyloid-related diseases are largely sporadic, although hereditary forms are documented in at least 
some patients; when sporadic, they have a relatively late age of onset (Table 1, column 5), 
suggesting that the phenomenon of protein aggregation, and its associated symptomatic conditions, 
originates primarily from a progressive loss of regulatory control with aging (29, 30).  
A small number of the disorders occur as a result of medical treatment (Table 1, column 5). 
Notable examples include dialysis-related amyloidosis associated with haemodialysis, injection-
localized amyloidosis linked to treatment for Type I diabetes, and iatrogenic Creutzfeldt-Jacob 
disease, which results from transplants or treatment with biological derivatives extracted from 
cadavers contaminated with aggregated forms of the prion protein. Several other diseases associated 
with the prion protein are also transmissible: ritualistic cannibalism has been identified as the cause 
of the transmission of a prion disease, known as Kuru, in Papua New Guinea (31, 32), and a small 
number of people are thought to have contracted a new variant of Creutzfeldt-Jacob disease 
(nvCJD) by consuming carcasses from animals infected with the bovine form of the disease (32, 
33). The causes of the transmission of these prion diseases are now under strict control with no new 
cases diagnosed over the past few years. There are reports that other amyloid-related diseases may 
be transmissible under laboratory conditions, but no evidence has been found for such events under 
normal conditions. 
 
Genetics of amyloid-related diseases (1225) 
Familial forms of amyloid-related diseases are often related to specific mutations within the gene 
encoding the peptide/protein that converts into amyloid fibrils (Table 2, column 5). Studies of the 
mechanisms by which these mutations are pathogenic have revealed that they often increase the 
propensity of the protein to aggregate, either directly or indirectly. There are, for example, over 100 
mutations linked to hereditary forms of transthyretin amyloidosis that are known to lead to 
destabilisation of the native tetrameric form of the protein, resulting in an enhanced population of 
the amyloidogenic monomer. Indeed, the in vitro amyloidogenicity of the natural TTR variants was 
found to correlate with a combination of their effects on the thermodynamic and kinetic stability of 
the tetrameric form, with all the variants having a stability score lower than wild-type TTR (15). 
Similarly, within a group of eight pathogenic mutations so far identified for lysozyme, the two most 
widely studied substitutions (I56T and D67H) are known to destabilise the native fold and increase 
the fractional population of a locally unfolded native-like state (34, 35). Formation of partially 
unfolded states facilitates aggregation as hydrophobic groups and segments of the polypeptide 
backbone that are buried and engaged in structure formation in the native state become available for 
intermolecular interactions. 
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A similar situation is evident from studies of the 19 pathogenic mutations known to be 
associated with systemic ApoAI amyloidosis. The mutations have been found to induce 
destabilisation of the dimeric lipid-free folded state, facilitating the exposure of amyloidogenic 
regions of the sequence; in this case, however, the loss of stability enables proteolysis to occur and 
generate a series of N-terminal unstructured fragments that are highly amyloidogenic (36, 37). In 
addition, some mutations have been reported to increase the rate of aggregation of the fragments 
themselves (36), and others have been suggested to promote dissociation of the full-length native 
dimer from the high-density lipoprotein (HDL) surface (37). Similarly, four mutations have been 
found in gelsolin as causative agents of Finnish type familial amyloidosis. Two of the variants 
(D187N and D187Y) have been widely studied and have been found to destabilise the native state 
of the protein by abolishing the ability of the second domain of the protein to bind Ca2+ (38), 
causing it to become susceptible to proteolytic cleavage and to generate highly amyloidogenic 
fragments (38-40). Overall, in the case of all four of these very different globular proteins, the 
pathogenic mutations destabilise the native states, making them susceptible to aggregation either 
directly or following proteolytic cleavage.  
A variety of origins of pathogenicity have been identified for the ca. 50 known mutations of 
 responsible for frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17). 
Most of the mutations have long been known to cause a loss of binding of  to microtubules, 
resulting in unfolding of the protein to its intrinsically disordered unbound state; several of the 
mutations also increase the aggregation rate of the resulting unfolded protein (41). Approximately 
10 of the known mutations of  are pathogenic through a very different and particularly interesting 
mechanism, as they cause alternative splicing of the pre-mRNA of  generating a highly 
amyloidogenic isoform, in addition to the normal sequence (42). 
The A40 and A42 peptides associated with familial Alzheimer’s disease and with 
hereditary cerebral haemorrhage with amyloidosis have been studied intensively and represent a 
particularly important source of information on the mechanism by which mutations are pathogenic. 
26 mutations map onto the gene coding for the precursor APP protein, all of which are located 
within or near the region coding for the A42 peptide that is generated by proteolysis (residues 672-
713). One double mutation (K670N-M671L) is located immediately before the cleavage site for the 
-secretases that generate the N-terminus of A. Fourteen mutations are downstream of the 
cleavage sites for the -secretases that generate the C-terminus, whereas the other eleven mutations 
are within the A42 region itself. The mutations following the C-terminus increase the specificity of 
-secretase for cleavage sites of APP so that the proportion of the 42-residue isoform of A is 
increased relative to the less amyloidogenic 40-residue form (43, 44). The K670N-M671L double 
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mutation at the N-terminus, the A673V recessive mutation and the A692G mutation, render the 
APP a better substrate for the -secretases BACE1 and BACE2, with the consequent 
overproduction of both forms of A (45, 46). Among the remaining nine mutations within the A42 
sequence itself, the E693Q, E693G, E693K, ∆Glu693, D694N and A713T mutations have been 
found to have no effect on the specificity of any of the secretases (47-50), while the effects of the 
other three mutations have not yet been reported. Nevertheless, all nine mutations are expected on 
theoretical grounds to increase the aggregation rate of the intrinsically disordered A peptides, and 
for a number of them the predictions have been verified experimentally (47, 51, 52). 
Six pathogenic mutations of -synuclein, a protein that similarly to A is intrinsically 
disordered, have been associated with familial forms of Parkinson’s disease, namely A53T, A30P, 
E46K, H50Q, G51D and A53E. Although there is evidence that the mutations can influence very 
significantly the rates of the various steps involved in amyloid formation, no clear links between 
these rates and the onset of disease have yet been established (53, 54).  
Another interesting mechanism by which mutations can become pathogenic is a change in 
the stop codon for translation. The three known mutations of corneodesmosin associated with 
hypotrichosis simplex of the scalp (Q168X, Q183X Y207X) insert a nonsense stop codon in the 
middle of the coding sequence, resulting in the formation of a truncated protein that is unable to 
fold and is therefore highly aggregation prone (55). By contrast, the two known mutations of the 
BRI gene associated with familial British dementia and familial Danish dementia, respectively, and 
the four known mutations of ApoAII associated with ApoAII amyloidosis, change the natural stop 
codon into a coding trinucleotide (56-59). This change results in the generation of polypeptide 
chains with undesired C-terminal extensions, which increase the amyloidogenicity of the whole 
polypeptide as a result of their unfolded nature and high intrinsic aggregation propensity (60). In 
addition, there are several disorders associated with the elongation of the amyloidogenic CAG 
repeat expansion within a gene, as occurs for the exon 1 of the huntingtin gene as well as for other 
genes coding for other polyQ containing proteins (61). Another very important type of mutation 
causes a duplication or triplication of the gene, resulting in a higher concentration of the 
amyloidogenic protein as occurs for the APP gene / A peptide in familial forms of Alzheimer’s 
disease (62), as well as the SNCA gene / -synuclein in familial Parkinson’s disease (63, 64). 
It is clear from examination of the data available at this point in time that all the familial 
mutations involving the sequences of the proteins undergoing amyloid fibril formation favour the 
aggregation process through one or more of the mechanisms described above and summarized 
schematically in Figure 2. This universal link between pathogenic mutation and aggregation 
provides clear genetic evidence that protein aggregation is a primary event in the pathogenesis of 
the corresponding diseases, rather than a secondary effect. Moreover, investigation of the 
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mechanisms of action and effects of such mutations provides vital evidence about the mechanisms 
and critical steps in protein aggregation that give rise to disease (Figure 2). 
 
THE STRUCTURES AND PROPERTIES OF AMYLOID FIBRILS 
 
General Characteristics 
Amyloid fibrils, whether extracted from patients or generated in the laboratory, are thread-like 
structures that are typically 7-13 nm in diameter, as observed by EM and AFM techniques, and 
often microns in length. They are generally composed of 2-6 protofilaments, each about 2-7 nm in 
diameter, that often twist around each other or associate laterally as flat ribbons that are 2-7 nm 
high and up to 30 nm wide, although mono-protofilament fibrils have also been observed (65, 66). 
The fibrils possess a cross- structure, in which -strands are oriented perpendicularly to the fibril 
axis and assembled into -sheets that run the length of the fibrils, as detected initially using X-ray 
fibre diffraction (67), with recent support from FTIR spectroscopy, ssNMR and X-ray 
crystallography (65, 68-69). The existence of such structure is characteristically monitored by the 
binding of dyes, such as thioflavin-T (ThT) or Congo red (CR), or their derivatives, which are 
thought to form ordered arrays along the lengths of the fibrils that give rise to specific spectral 
responses (70, 71). These three features, a fibrillar morphology, cross- structure and characteristic 
tinctorial properties, are universally accepted as the hallmarks of amyloid structure, and any given 
protein aggregate needs to display all of them to be classified as such. 
The physicochemical properties of amyloid fibrils have been examined in detail by a variety 
of techniques, notably AFM, and found to be remarkably highly organised with persistence lengths 
on the order of microns and with a tensile strength that approaches that of steel (6). The mechanical 
strength and stability of amyloid fibrils can be attributed primarily to the formation of the extended 
-sheets that are characteristic of the amyloid architecture, a feature that is enhanced by the 
presence of multiple closely interacting sheets as well as further association of protofilaments to 
form higher order structures. An intriguing aspect of the amyloid structure is the close similarity of 
the fibrils formed by different polypeptide chains. This generic nature (where ‘generic’ indicates 
common but not identical) can be attributed to the dominance of the main chain interactions that are 
common to all polypeptide molecules, with variations on this common theme resulting from 
differences in amino-acid sequences and chain lengths, and other factors including the solution 
conditions. Recent experimental, theoretical and computational studies have provided detailed 
explanations for the underlying architecture, including such characteristics as the similarities in the 
lengths of the -strands, the low degree of twist in the -sheets, and the fact that short peptides can 
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assemble into three-dimensional crystals whilst the most regular structures attainable by longer 
sequences are one-dimensional filamentous assemblies (6). 
It is increasingly clear that the amyloid form of a protein molecule can be even more stable 
than the native state, whether intrinsically disordered or globular, even under physiological 
conditions (72-74). Such a situation is particularly true in the case of short sequences, as longer 
sequences not only incorporate only a fraction of their polypeptide chains into the cross- core but 
also have an increasing probability of being unable to generate highly ordered structures from 
unfolded segments of their sequences (73). In accord with this conclusion it is evident that all the 
polypeptides associated with amyloid formation in vivo, both in disease and for functional 
purposes, have relatively short chain lengths (Table 1), whereas proteins forming amorphous or 
native-like deposits in pathology are, on average, much longer (Table 2). Given the high stability 
and generic nature of amyloid fibrils it is not surprising that, following initial reports (2, 3), a large 
number of very different proteins that have no link with human disease have been converted in vitro 
into amyloid-like fibrils that are morphologically, structurally and tinctorially indistinguishable 
from those associated with amyloid deposits in pathology. 
 
Molecular Structures of Amyloid Fibrils 
The utilisation of ssNMR, cryo-EM and X-ray microcrystallography has generated a dramatic 
increase in our knowledge of the detailed structures of amyloid fibrils from a wide variety of 
peptides and proteins. Of particular importance were two early structural models of A40 
protofilaments, which revealed the overall similarities but differences in detail between different 
polymorphic forms of this important system (65, 75). The models were developed from structural 
constraints obtained using ssNMR data, TEM imaging and mass-per-length measurements obtained 
with STEM (Figure 3a). In one model the protofilaments are 6 nm in width and associate laterally 
to form “striated ribbons” (75), whilst in the other the protofilaments are 7 nm in width but do not 
associate laterally (65). In both cases, each polypeptide chain has a flexible N-terminal segment and 
residues 10-22 and 30-40 form a pair of -strands that are linked by a long loop. Both -strands are 
incorporated into distinct, stacked -sheets, lying along the axis of the protofilaments with all 
strands arranged in a parallel, in-register fashion and having a number of intermolecular side-chain 
contacts.  
 Despite these common structural features, in the polymorph with striated ribbons, each 
protofilament consists of four -sheets and has overall two-fold symmetry (Figure 3a, top), whereas 
in the second polymorph six -sheets are present, arranged in three-fold symmetry (Figure 3a, 
bottom). Differences between the two polymorphs also involve sidechain-sidecain interactions. 
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Other structures of A40 and A42 protofilaments have been proposed more recently using ssNMR, 
indicating yet further that different polymorphs can be obtained with the same peptide (76-78).  
Structural models of protofilaments deduced from ssNMR and electron microscopy 
restraints have also been described for human IAPP (79, 80), medin (81), HET-s from P. anserina 
(66, 82) and polyglutamine containing peptides (83). ssNMR structural data were also obtained for 
other disease-associated systems, although analysis of these systems has not yet led to detailed 
models of the protofilaments, but has been limited so far to the identification of those regions of the 
sequences that form -strands in the fibrils. Examples include fibrils from human PrP23-144 (84), 
ovine PrP25-233 (85), human insulin (86), transthyretin (87), the K19 fragment of tau (88), calcitonin 
(89), 2-microglobulin (90), and a number of polymorphs of -synuclein (91-95). 
Important contributions to our knowledge of the types of interactions likely to be present in 
amyloid fibrils have also been provided by X-ray diffraction studies of microcrystalline arrays of 
short peptides, typically containing less than 10 residues (Figure 3b). Such studies can give rise to 
high-resolution structures, and some 30 systems have now been studied in this way, revealing a 
series of common characteristics, such as the participation of each peptide molecule in a single -
strand, the in-register alignment of the -strands in the -sheet to optimize the intermolecular 
interactions, the presence of pairs of -sheets parallel to each other and propagating along the fibril 
axis, and the tight inter-digitation of the side chains within such pairs (69). The various structures 
have been divided in different classes, depending on whether the -strands in the same sheet are 
parallel or antiparallel, whether the adjacent sheets interact face-to face or face-to-back and whether 
the corresponding strand termini from different sheets point to the same or opposite directions (69). 
In addition, important information has emerged from X-ray diffraction studies of fibres or powders 
formed by short peptides or polyglutamine-containing peptides, exploiting the relative simplicity of 
the patterns from short or repetitive sequences of the peptides studies in this way (96-98). Recently, 
a novel micro-electron diffraction method has been applied to determine the structure of an 11-
residue peptide assembled in nanocrystals at 1.4 Å resolution, further enlarging our technical 
abilities to solve the structure of amyloid assemblies at atomic resolution (99). 
A particularly interesting and important structural study of a fibril is that determined at 
atomic resolution for the prion domain of HET-s from P. anserina (residues 218-289) using ssNMR 
(66, 82). The fibril is a single protofilament consisting of a left-handed -solenoid or -helix 
structure in which each molecule contributes to two windings of the -solenoid and eight -strands 
(Figure 3c). The first four and last four strands contribute to the first and second windings, 
respectively, so that 4 parallel -sheets are generated that propagate along the fibril axis. In this 
structure each strand interacts with a different strand of the same or different molecule, so that the 
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arrangement is parallel but not in-register. A similar -solenoid structure has recently been 
proposed also for the human prion fibril on the basis of X-ray fibre diffraction data, although in this 
case each molecule contributes to four, rather than two, windings of the -helix (100). Although 
such a structure can be one of many possible polymorphs, it is tempting to speculate that the -
solenoid structure is a specific ‘evolved’ structure responsible for infectivity of prion proteins, and 
so is distinct from the ‘default’ amyloid structure. As it does not have a double sheet it may be more 
easily fragmented than classic amyloid structures, potentially a key element in explaining 
transmission in prions, although such assertions await experimental confirmation. 
Other interesting structural models that have been characterised are of native-like amyloid 
fibrils, where the folded conformation is largely maintained in the fibrils, such as in fibrils of wild-
type transthyretin (101-103), the S134N mutant of superoxide dismutase type 1 (104) and full-
length wild-type cystatin c (105). It is clear that only proteins predominantly formed by -sheet 
structure, such as the three examples mentioned above, can maintain a native-like structure in the 
amyloid fibrils and give rise to the cross- structure concomitantly. None of the amyloid fibrils so 
far characterised by normally folded proteins were found to consist of run-away domain swapped 
structures. These structures have mainly been identified within crystals, in the absence of a cross- 
structure. They have also been identified in non-crystalline amyloid-like fibrils possessing a cross- 
structure, but in this case domain swapping is promoted by the presence of unnatural engineered 
disulphide bridges or polyQ tracts (106, 107). 
 
Common Features of Amyloid Structures 
The large number of structural models, and more recently high-resolution atomic structures, of 
amyloid fibrils that are now becoming available makes it possible to begin to identify and to 
rationalise their important common and distinctive features. First, it is evident that polymorphism is 
frequent, i.e. that the same protein sequence can give rise to fibrils that differ both in the molecular 
structures of their protofilaments and the overall morphology of the mature fibrils. A remarkable 
example of polymorphism is represented by TTR fibrils, where an essentially native-like stacking 
of transthyretin molecules has been described by three groups (101-103), whilst the structures 
described in another report involve a global reorganization of the structure in the fibrillar state 
relative to the native fold (87).  In a manner similar to that observed in many crystalline systems, a 
given polymorph can seed the same type of structure, as shown for A40 twisted fibrils and striated 
ribbons formed under quiescent and agitated conditions, respectively, which propagate the same 
structure even if they are used to seed fibril growth under the different conditions (108). A similar 
pattern of behaviour has been observed for many other systems, such as two types of insulin fibrils 
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(109) and -synuclein fibrillar assemblies (110). This concept is likely to be the underlying origin 
for distinct prion ‘strains’ (111). 
Polymorphism is an inherent consequence of the generic ability of polypeptide chains to 
form amyloid fibrils. Unlike native folds that have been selected through evolution and are encoded 
in their amino acid sequences, the amyloid architecture is simply a consequence of the 
physicochemical properties of a polypeptide chain, and there are multiple ways that a given 
sequence can be incorporated in such structures. In the majority of cases, in the absence of 
evolutionary selection and optimisation, there is likely to be a multiplicity of structural 
arrangements of closely similar energy. Once a given type of assembly has been initiated, however, 
it will generally propagate because of the inherently stability of repetitive structures in highly 
organised systems and the high kinetic barriers that exist in the interconversion between 
polymorphs, a situation analogous to that observed in crystallography. 
A second recurrent theme that emerges from an analysis of the various amyloid structures is 
the structural organization of -strands in the core of the fibrils. The strands are found generally to 
interact to form -sheets with a parallel in-register arrangement, i.e. the individual strands all have 
the same N-terminal to C-terminal orientation, and residue i of one strand interacts with the 
equivalent residue i of the next strand. This arrangement is evident in all polymorphic forms of 
A40 and A42 fibrils so far characterized (65, 75-78, 112, 113), for all polymorphs of -synuclein 
(94, 95, 114, 115), for full-length and the K19 fragment of tau (88, 116), for IAPP (79, 117), 2-
microglobulin (118), medin (81) and various PrP fragments (84, 85, 119). The frequency of this 
parallel in-register arrangement relative to other alternatives can be attributed to both 
thermodynamic and kinetic factors, as it maximises the number of hydrogen bonds and hydrophobic 
interactions along the fibril axis. The out-of-register arrangement necessarily generates alternative 
interactions of hydrophobic-hydrophilic residues in the fibril direction, and so is likely to give rise 
to less stable structures. 
Alternative organisations of the -strands within fibrils are, however, found for small 
peptides, where an antiparallel arrangement is sometimes preferred to a parallel one; the small 
number of residues involved means the energetic penalty to be paid in breaking the parallel in-
register arrangement is relatively low and can largely be compensated by alternative interactions, 
for example by salt bridges contributed by amino acid residues with opposite charges at the N- and 
C-termini that are spatially close in the fibrils (69, 96). In the case of polyQ containing peptides, 
however, an antiparallel arrangement has been found for both long and short sequences where the 
alignment of glutamine residues along the fibril axis is present in both the parallel and antiparallel 
arrangements and is not compromised following any shift of the register in adjacent strands (83, 
97). Nevertheless, antiparallel arrangements have also been found for long sequences without 
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repetitive amino acid residues, such as in fibrils from calcitonin (89), some polymorphs of 
transthyretin (87, 102) and the D23N mutant of A40 (120). In the latter case, at least, it was shown 
that antiparallel structure coexists with the conventional parallel structure and represents a 
metastable polymorph that slowly converts into the parallel one (120). 
Except in the case of peptides of less than about 12 residues, only a fraction of the 
polypeptide chain is incorporated in the cross- core of the fibrils. It has been shown that the 
regions of the sequence of a given protein embedded within such core regions can be predicted 
from physicochemical properties such as the high density of hydrophobic groups, the small number 
of charges, the high propensity for -sheet structure and the presence of patterns of alternating 
hydrophilic and hydrophobic residues, leading to the explosive birth of a number of algorithms with 
predictive power (121). Figure 4 shows the comparison between the aggregation propensity profiles 
generated by one representative algorithm (122, 123) for four representative peptides/proteins, 
namely A, -synuclein, IAPP and the K19 fragment from tau, with respect to the experimental 
data available for the fibrils of these four systems. The excellent agreement between theoretically 
and experimentally determined sequence regions is evident, despite some variations resulting from 
fibril polymorphism, and provides strong support for the view that the inherent architecture of the 
amyloid structure is determined by the intrinsic properties of the main chain, and that a given 
sequence portion is incorporated with such a framework in ways that optimise the interactions 
between the various side-chains. 
The structures and structural models described above have been determined for fibrils 
formed entirely in vitro under carefully controlled conditions. Recently, however, fibrils amenable 
to TEM and ssNMR investigation have been generated in vitro from synthetic A40 but after 
seeding with material extracted post mortem from the brains of Alzheimer’s disease patients (77). 
After seeding with aggregates from two patients with different clinical histories, the fibrils were 
found in each case to have a single morphology, but one that differed in the two cases, and indeed 
from all the polymorphs previously characterized in vitro. This observation suggests that the 
specific environment within the brain influences strongly the initiation of fibril growth, and that the 
morphology formed in this process is then propagated as a result of the aggregates spreading 
throughout the brain (77). Similarly, tau fibrils produced from recombinant protein seeded with 
brain-derived paired helical filaments were found to be similar to those formed directly in the brain 
and different from those of heparin-induced fibrils formed in vitro (124). 
 
MECHANISMS OF AMYLOID FIBRIL FORMATION 
 
Descriptions of Protein Aggregation 
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One of the most significant recent advances in the study of protein misfolding and aggregation has 
been the development and application of robust experimental and mathematical techniques to 
analyse the kinetics of amyloid fibril formation to yield insight into mechanism. It has long been 
recognised that the process underlying the conversion of a normally soluble peptide or protein into 
an aggregated state, as in the more familiar process of molecular crystallisation, involves nucleation 
and growth steps. Indeed, when the quantity of fibrils formed during an aggregation reaction is 
measured as a function of time, for example by monitoring turbidity or ThT fluorescence, sigmoidal 
kinetics are frequently observed reflecting three distinct phases, generally described as a lag phase, 
an exponential phase (also called an elongation, growth, polymerisation or fibrillation phase) and 
an equilibrium phase (also called a plateau or saturation phase) (125-128). 
In the simplest type of ‘nucleated polymerization’ mechanism, monomers that are 
completely or partially disordered convert into nuclei through a thermodynamically unfavourable 
process that takes place early in the lag phase (Figure 5A, red arrow pathway); fibrils then grow 
from these nuclei through the addition of monomers at the fibril end (127); Such nuclei are 
thermodynamically unstable and can be thought of as the smallest structures that are able to initiate 
fibril elongation, or the smallest species where the rate of further monomer addition exceeds that of 
monomer release (127). Nuclei can even be monomers with a well defined conformation (Figure 
5A) (129, 130). This model has been used to describe the aggregation of a range of systems 
including the prion protein (131), A40 and A42 (125), -synuclein (132), polyGln sequences 
(133), insulin (134) and others.  
In some cases, however, monomers convert rapidly into misfolded aggregates through a 
template-independent mechanism, with formation of ‘molten’ assemblies that lack the structural 
characteristics needed to grow into organised fibrils (Figure 5A, blue arrow pathway) (17). These 
initial aggregates can, however, undergo a structural reorganization to generate nuclei, on which 
other molten oligomers acquire the amyloid conformation through a templating or induced-fit 
mechanism at the aggregate ends (17). This leads eventually to the formation of fibrils (Figure 5A). 
Unlike nucleated polymerisation, in this ‘nucleated conformational conversion’ mechanism, the 
rate-limiting step is the conversion of the initially formed oligomers into the growth-competent 
nuclei. A nucleated conformational conversion model has been used to describe amyloid formation 
by a range of systems including the NM region of the yeast prion Sup35p (17), ADA2h (135), the 
prion protein (136), A40 (12), huntingtin exon 1, (137), IAPP (138) and hen lysozyme (139). 
In the case of globular proteins, the usually compact and highly cooperative structures bury 
the most aggregation-prone regions of the molecules within the core of the protein. Thus, normally 
folded proteins need to convert into a partially unstructured ensemble that is competent for 
aggregation, before aggregation can proceed through one of the mechanisms described above 
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(Figure 5A) (140). In addition, extensive studies have shown that natively folded globular proteins 
possess a small but significant tendency to convert into the amyloid state without crossing a major 
energy barrier for unfolding, by populating native-like conformations as a consequence of local 
unfolding or thermal fluctuations (Figure 5A) (140). In these native-like states, aggregation-prone 
segments that are normally buried or structured in the fully folded state become exposed to the 
solvent or gain flexibility, triggering the formation of native-like aggregates, which then convert 
into amyloid-like oligomers and fibrils (Figure 5A, green arrow pathway), in a process similar to 
the nucleated conformational conversion described above. Processes of ‘native-like aggregation’ of 
this type have been described experimentally for Cu,Zn-superoxide dismutase (141), 2-
microglobulin (14), transthyretin (102, 103) lysozyme (43), acylphosphatase from S. solfataricus 
(142), a mutant of the fyn SH3 domain (143), the TTR-like domain of carboxypeptidase D (144) 
and others. 
In the aggregation reaction of any system, alternative pathways are likely to exist for the 
stage at which conformational conversion from a non-amyloid to an amyloid conformation occurs 
(145). Thus, the three models described above are likely to be extreme cases of a continuum of 
mechanisms where multiple pathways are accessible and selected depending on experimental 
conditions, protein sequence and conformational state adopted by the amyloidogenic monomer. 
Indeed, the multiplicity of aggregation processes has similarities to those observed for the folding of 
globular proteins where parallel pathways and reorganisation steps have been described in many 
cases. In the next section we describe the progress made recently to address the inherent complexity 
of the aggregation process.  
 
Quantitative Analysis of Protein Aggregation Mechanisms 
It has long been known that ‘secondary’ processes can be important in the kinetics of molecular 
self-assembly. Of particular interest are ‘fragmentation’ events, in which a growing aggregate 
breaks into smaller species, and ‘secondary nucleation’ reactions, in which the surfaces of growing 
aggregates catalyse the formation of new clusters of monomers that act as nuclei (146-150). Both of 
these processes are able to increase the number of growth-competent species and hence cause the 
aggregation rate to accelerate as the reaction progresses. 
The inclusion of secondary processes increases yet further the challenges involved in 
interpreting the kinetics of protein aggregation. However, a ‘master equation’ can readily be 
generated to include all the different steps of the overall process, such as primary nucleation, fibril 
elongation, secondary nucleation and fibril fragmentation. Although the generalised master 
equation contains a set of non-linear differential equations, it has proved possible to generate exact, 
or very good approximate, solutions, by exploiting a range of innovative mathematical approaches 
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(146, 148-150). It was possible to determine the rate constants for the various microscopic steps 
from global fits to a series of kinetic traces measured for the overall fibril formation reaction, 
provided the latter are measured over a range of protein concentrations and with high accuracy 
(128, 146, 148-150). This allows the time courses of the concentrations of the various species to be 
determined for a given aggregation process, with a quantitative reconstruction of its mechanism. 
Application of this analytical approach has shown that the lag and exponential phases do not 
generally correspond in a simple manner to the molecular events of nucleus formation and fibril 
elongation, respectively, but each results from a combination of molecular events involving primary 
nucleation, fibril elongation, secondary nucleation and fibril fragmentation (128). Consequently, a 
significant quantity of fibrils resulting from the elongation of primary nuclei may be formed during 
the lag phase, and the formation of nuclei can be of major significance during the exponential 
phase, when the fibril population is sufficiently large to generate new nuclei through secondary 
nucleation. Indeed, secondary nucleation and fragmentation, rather than elongation, can be the 
dominant processes contributing to fibril growth during the exponential phase of the aggregation 
kinetics (128, 146). 
Very high quality kinetic data have now been obtained and analysed for a range of protein 
systems in vitro, notably A42 (148), A40 (149), -synuclein (150), polyQ-peptides (151) and 
Ure2p (152). The results reveal remarkable variations in the dominant contributions to the initiation 
and proliferation of amyloid fibrils. Thus, for example, secondary nucleation plays a key role in the 
aggregation kinetics of the A peptides, being the major contributor to the rapid growth phase of 
both A40 and A42 (148, 149). By contrast, under quiescent conditions the aggregation of -
synuclein in aqueous solution at physiological pH occurs at a negligible rate because the rate of 
primary nucleation is extremely slow (150). The primary nucleation reaction can, however, be 
accelerated dramatically in the presence of lipid vesicles (153) and the secondary nucleation rate 
increases by several orders of magnitude by lowering the pH to between 5 and 6 (150). 
 
Intermediate Species in Fibril Formation 
Of particular significance in the context of amyloid fibril formation are pre-fibrillar species, often 
called oligomers, not just because of their importance in the mechanism of the self-assembly 
process itself, but also because they are thought to represent the most pathogenic species in the 
diseases associated with amyloid fibril formation (see next section below). It is this association with 
pathogenesis that has led to extensive searches for well-defined oligomers in protein aggregation 
reactions, with the aim of isolating them, determining their structures and the structural 
determinants of their pathogenicity. This task is, however, complicated by the structural 
heterogeneity and transient nature of any given oligomer population, and by the fact that there are 
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frequently multiple parallel pathways to oligomeric species leading to the existence of many 
accessible polymorphs, depending on the exact experimental conditions. 
A variety of oligomers has been isolated and characterised for the widely studied A40/A42 
peptides and given a wide range of names, such as globulomers, amylospheroids, paranuclei, 
pentamers, A*56, SDS-stable dimers/trimers, protofibrils, ADDLs, prefibrillar and fibrillar 
oligomers, spherical amyloid intermediates (18, 154-164). Comparison between structural 
characteristics of the various species reported in these studies indicates that the average content of 
-sheet structure generally increases with the molecular weight, suggesting that an increase in size 
(i.e. with the number of molecules within an oligomer) stabilises their -sheet structure. Such 
structure has generally been shown to involve both antiparallel (158, 165) and parallel and out-of-
register strands (166), compared to the structure of the fibrils where the -strands are arranged in a 
parallel and in-register manner (65, 75, 76, 78, 113). Interestingly, an exception to this rule appears 
to be the 15-35 nm spherical amyloid intermediates, which are the largest oligomers so far 
characterised (> 650 kDa) and shown to possess an in-register parallel cross- structure very similar 
to that found in the fibrils (161). 
When various oligomeric forms of A have been found to appear sequentially during an 
aggregation reaction, the first species have been reported to be unstructured with the -sheet 
containing species only appearing later (18, 161, 167-166). The largest oligomers with the highest 
-sheet content, such as those described as fibrillar oligomers, annular protofibrils, curvilinear 
protofibrils and amyloidspheroids, have been found to represent off-pathway species that need to 
dissociate prior to forming amyloid fibrils (165, 168, 169). This conclusion is consistent with the 
large size, presence of antiparallel (or parallel out-of-register) -sheet structure, that needs to be 
substantially reorganised to form the parallel in-register structure of the fibrils, and by kinetic tests 
showing that seeded and unseeded fibril formation is slower in the presence of such species than in 
the presence of monomers (165, 168, 170). 
A variety of oligomeric species has also been described for -synuclein. Of particular 
interest are the results of single molecule studies where two distinct types of oligomers, named type 
A and B, were found to form sequentially with a slow transition between the two forms (13). Type 
A oligomers form only transiently, have a disordered secondary structure, are less compact and less 
highly organised, as revealed by FRET and proteinase K resistance, and are smaller (n < 10 mols) 
than type B oligomers. Later on, two distinct subgroups of type B oligomers have been identified 
and shown to contain 11-25 and 19-39 monomers and to have an antiparallel -sheet content of ca. 
30% and ca. 40%, respectively (171), showing again a direct correlation between -sheet content 
and size, in agreement with the A oligomer data. Other oligomers of -synuclein have been 
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isolated and characterised, all having sizes equal to or larger than that of the type B oligomers, but 
with similar  antiparallel -sheet structure and also being off-pathway (172, 173). 
When aggregation is initiated by intrinsically disordered systems, such as A and -
synuclein described above, the initial oligomers appear initially to adopt a disordered structure with 
more highly organised oligomers appearing later (12, 13, 17, 18, 22). Similar observations have 
been made for globular proteins that aggregate under denaturing conditions, such as the acid-
unfolded SH3 domain of bovine phosphatidylinositol 3-kinase at low pH (21) and yeast 
phosphoglycerate kinase (19). On the other hand, if aggregation of globular proteins is initiated 
under native conditions, the early aggregates formed at the beginning of the process may well 
display monomers populating native-like states, which later convert into -sheet containing 
protofibrils/fibrils, as found for insulin and acylphosphatase from S. solfataricus (16, 20).  
It therefore appears that the initial aggregates are affected by the structures of the 
aggregation competent monomers from which they are generated (Figure 1). Such early aggregates 
are typically small in size, do not bind amyloid specific dyes and do not exhibit a significant content 
of -sheet structure and compactness (Figure 5B). As aggregation proceeds, such oligomers 
undergo structural rearrangements into species stabilised by -sheet structure, generally antiparallel, 
with weak binding to ThT and Congo-red (Figure 5B). It is only later that species appear with a 
highly regular in-register parallel cross- structure and fibrillar morphology.  
 
THE MOLECULAR ORIGINS OF AMYLOID-RELATED PATHOGENICITY 
 
The Structural Determinants of Oligomer Toxicity 
It is increasingly accepted that the pathogenic species in non-neuropathic systemic or localised 
amyloidoses are both the extracellular amyloid deposits affecting organ architecture and the protein 
oligomers that form as on- or off-pathway species in the process of their formation or released by 
mature deposits, causing direct cellular damage (174, 175, 176). However, in neuropathic diseases 
involving the central nervous system, it is increasingly clear that the pathogenic species are the 
oligomeric forms generated in the process of aggregation (111, 177-179). The fibrils are, however, 
far from innocuous material as they can deplete key components of the protein homeostasis network 
(74, 180), as we discuss further below, serve as a reservoir of protein oligomers that can be released 
(13, 155; 181, 182), and act as potent catalysts for the generation of toxic oligomers through 
secondary nucleation (128, 148-152). Occasionally, some polymorphs have also been found to be 
highly toxic (94).  
It was evident prior to 2006 that the most toxic aggregates were likely to be pre-fibrillar 
oligomeric species, but since then the progressive elucidation of oligomer structure has started to 
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reveal the structural determinants of the manner in which these species cause cellular dysfunction. 
The exposure of hydrophobic groups on the oligomer surface appears to be a major determinant of 
oligomer-mediated toxicity. Indeed, for a range of proteins, oligomeric species of similar sizes and 
morphologies, but having very different toxicities, have been isolated and shown to differ in their 
solvent-exposed hydrophobicity, for example for HypF-N (183), A42 (184), -synuclein (13) and 
the NM region of Sup35p (185). Moreover, remarkable correlations have been observed between 
the toxicity of different forms of oligomeric species, produced in vitro and then added 
extracellularly to cell cultures, and their solvent exposure determined with ANS binding (186). It 
has also been shown in a similar manner that highly amyloidogenic proteins expressed 
intracellularly in human cells have levels of toxicity that increase with the exposure of hydrophobic 
clusters on the surfaces of the aggregates (187). 
Another important determinant of the toxicity of misfolded oligomers appears to be their 
size. In this regard, the results reported on the A40 and A42 oligomers represent again an 
important source of information as the toxic effects on cultured cells have been reported by 
different authors for a variety of different preparations using the MTT reduction assay and 
including data for peptide concentrations in the range 2.0-2.7 µM (monomer equivalent). This 
analysis indicates that monomers, dimers and trimers (MW 4-14 kDa) show minimal toxicity (158, 
161, 167), that the maximum toxicity in terms of monomer equivalents is exhibited by small 
oligomers, such as prefibrillar oligomers with MW 18-90 kDa (157, 158) and ADDLs with MW 36-
72 kDa (188, 189) and that it then decreases with oligomers having increasing size, in the order 
fibrillar oligomers with ca. 68-104 kDa (165), annular protofibrils with ca 250-400 kDa (158) and 
amylospheroids with  ca. 670 kDa (160), up to the fibrillar structures that retain residual, yet 
significant, toxicity (161, 162). Although such a wealth of information has not yet been reported for 
-synuclein, a report on two types of oligomers of this protein with the same degree of -sheet 
structure and solvent-exposed hydrophobicity indicates that the smaller species are the more toxic 
(173). In agreement with these observations it has been found that the induction by chaperones of 
the further assembly of pre-formed oligomers of A42, IAPP and HypF-N into large aggregates in 
the absence of any structural reorganisation results in a substantial reduction in toxicity (190-192).   
A plausible explanation of the importance of small size in oligomer toxicity is the large 
surface/volume ratio featured by small species, which increases the extent of active surface per 
protein molecule, and also the high diffusion coefficient exhibited by such species, which allows 
them to diffuse more rapidly, and hence form aberrant interactions more readily (191). However, 
monomers and low molecular weight oligomers are likely to have their hydrophobic groups too 
distributed over their surfaces, providing an explanation as to why they are not deleterious. As a 
further corroboration of the importance of such characteristics, a series of oligomeric species of 
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HypF-N have been generated using mutational different variants of the proteins and different 
solution conditions; the toxicity of the oligomers was found to correlate strongly and inversely with 
their size and directly with their surface hydrophobicity in a three dimensional plot (193). 
As far as the degree of -sheet structure is concerned, a detailed review of the literature 
shows that structured oligomers appear to be either more or less deleterious than unstructured ones 
depending on their size and solvent-exposed hydrophobicity, which again seem to be the most 
important factors in this regard. Nor does the shape of the oligomers appear to be very important: 
the interesting hypothesis that oligomers exert their toxicity species by forming annular structures 
with a pore-like morphology does not appear to be supported by recent experimental data (158; 194, 
195), and indeed the appearance of such structures may simply be a characteristic of the inherent 
architecture of the water-mediated face-to-face packing of pairs of β-sheets rather than a unique 
structural feature of the oligomers (171). 
With the identification of at least some of the structural determinants driving oligomer 
toxicity, the question arises as to ‘which’ and ‘how’ small and hydrophobic aberrant species can 
cause dramatic cell dysfunction. The aggregation of a protein from its soluble state will invariably 
generate a large ensemble of aggregated species, the populations of which will vary with sequence, 
time, and conditions. Most of these ‘misfolded’ oligomeric species are likely to be toxic to some 
degree because of their small size and because they will inevitably expose on their surfaces clusters 
of hydrophobic groups that are normally buried in globular proteins or that are rare and highly 
dispersed in intrinsically disordered proteins. A wide variety of biochemical, cytological, and 
physiological perturbations has been identified following the exposure of neuronal and non-
neuronal cell cultures, primary neurons, hippocampal slices and whole animals to such species, 
regardless of their precise identity. The oligomers have also been reported to interact with a large 
number of molecular species, leading to a multiplicity of factors influencing toxicity and also a long 
list of possible molecular targets for drug discovery and therapeutic intervention. In the case of 
Alzheimer’s disease, for example, extracellular protein oligomers have been reported to interact 
with the phospholipid bilayers of the cell membrane, NMDA and AMPA receptors, the 
metabotropic glutamate receptor 5, the insulin receptor, the nicotinic acethilcholine receptor 7-
nAcChR, PrPc, and other cellular components and membrane receptors. (178). 
Hence, it is important to recognise that there is no unique ‘toxic agent’ associated with each 
of the various diseases. The large network of aberrant interactions that such species can generate 
indicates that it is extremely unlikely that there is a unique molecular interaction, a unique 
mechanism of action, or a unique cascade of cellular events associated with a given disease. 
Instead, the toxicity of the protein aggregates that result in disease is likely to result from their 
intrinsic misfolded nature and their structural heterogeneity. Such properties will cause them to 
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engage in a multitude of aberrant interactions with a range of cellular components, including 
phospholipid bilayers, protein receptors, soluble proteins, RNAs, small metabolites, any or all of 
which has the potential to cause cellular damages and ultimately cell death. 
 
Protein Metastability and the Proteostasis Network 
Given the intrinsic propensity of proteins to form thermodynamically stable amyloid fibrils and the 
detrimental effects of protein misfolded oligomers, it is not surprising that all living organisms have 
developed a dedicated network of cellular machineries to assist protein folding and counteract 
protein aggregation. Such a network is generally referred to as proteostasis network (PN) and is 
constituted by the translational machinery, molecular chaperones and co-chaperones and protein 
degradation apparati such as the ubiquitin proteasome systems (UPS) and autophagy (74, 180). 
Molecular chaperones and co-chaperones have been grouped in distinct families, including 
ribosome-binding chaperones, Hsp40s, Hsp70s, chaperonins, Hsp90s, Hsp100, prefoldins, small 
Hsp and TRP-domain containing co-chaperones. This large body of proteins, amounting to 332 in 
the human proteome (196), have long been recognised to assist protein folding, aid assembly of 
complexes, inhibit protein aggregation and mediate protein degradation via the UPS or autophagy 
(74, 180). Two novel and previously unappreciated functions of chaperones in higher eukaryotes 
have been shown to be the binding to preformed aggregates to either promote their disassembly 
(197) or convert them them into large assemblies (190, 191), therefore preventing their toxicity in 
both cases. 
Importantly, cells also use integrated processes where sensors of misfolded species 
ultimately activate the transcription of genes coding for PN components, such as the heat shock 
response in the cytosol and nucleus (HSR), the unfolded protein response in the endoplasmic 
reticulum (UPRER) and in the mitochondria (UPRmito) (180). In addition to these cell-autonomous 
controls, it is increasingly recognised that cells also communicate local environmental stresses to 
distal cells by cell-nonautonomous mechanisms that utilise specific sensory neurons and 
transcellular chaperone signalling (180). 
The aggregation of a polypeptide chain is also intrinsically inhibited by its amino acid 
sequence that is carefully selected by evolution to promote folding into a compact stable structure, 
which generally possess a very low propensity to self-assemble, and to minimise its aggregation 
propensity when adopting a fully or partially unfolded state (198). Even transcriptional expression 
and half life of proteins are finely regulated depending on their intrinsic aggregation propensities 
(199, 200).  
 In spite of all all these expedients that have co-evolved in any living organisms, protein 
aggregation inevitably occurs as a consequence of aging (30, 74, 180), environmental stress and 
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certain aspects of ‘lifestyles’, such as obesity (74, 174, 180, 201), sustained increases in protein 
concentration (14, 24, 89, 201, 202, 203), ingestion or iatrogenic transmission of pre-formed 
aggregates (Collinge and Clarke, 2007), mutant proteins with high propensity to aggregate (15, 34, 
36, 40, 41, 44, 54-59, 61, 84, 105), or aberrant proteolytic cleavage (36, 40, 44). All these factors 
readily promote aggregation due to their ability to generate misfolded protein species leading the 
PN to collapse.  
Aging is undoubtedly the major risk factor for all protein deposition diseases, even in the 
absence other obvious protein misfolding agents. Evidence is accumulating that a progressive 
failure of the PN occurs with aging in humans: chaperones decrease their abundance in human 
brains because sequestered by accumulating protein aggregates and because the expression of ca. 
30% of them is down-regulated with aging (196); an age-related decline of the UPS activity has 
also been repeatedly observed in humans and attributed to a variety of factors, such as a decrease of 
proteasome number, transcriptional down-regulation or structural modification of some of its 
subunits, defective chaperone-mediated recruitment of proteins targeted for degradation, 
accumulation of cross-linked proteins difficult to digest, etc. (204); Both macroautophagy and 
chaperone-mediated autophagy also decrease their efficiency as a result, among other factors that 
remain to be identified, of the transcriptional down-regulation of Atg proteins and decreased levels 
of lysosomal membrane receptors, respectively (205). The age-related increase of oxidative stress 
and decrease of mitochondrial function and ATP production further worsen the PN efficiency. In 
this scenario of defective PN, protein aggregation becomes more difficult to be controlled. Notably, 
evidence exists that the age-related accumulation of protein aggregates is both an effect and a cause 
of PN decline, driving a vicious cycle that ultimately leads to PN collapse (74, 180). There is a 
narrow boundary between health and disease, and subtle changes caused, for example, by genetic 
mutations, environmental stress or increasing age, can result in the initiation of the aggregation 
process leading to the disruption of PN. As a consequence, all the aforementioned changes of the 
PN are further exacerbated in neurodegeneration as opposed to normal aging (196, 204, 205). 
 It is also starting to emerge why only a few proteins aggregate in pathological states despite 
the widely demonstrated generic potential of proteins to form amyloid-like fibrils. Following the 
demonstration that the mRNA transcriptional levels and intrinsic aggregation propensities are 
inversely correlated (199, 206), it was postulated that proteins need to have well defined levels of 
abundance on the basis of their intrinsic solubility. Proteins forming amyloid deposits in pathology, 
co-aggregating with extracellular amyloid plaques and intracellular neurofibrillary tangles in 
Alzheimer’s disease, with Lewy bodies in Parkinson’s disease, and with aggregated model proteins 
in human cell cultures, all have values of aggregation propensity and mRNA expression higher than 
those required to remain soluble, i.e. they are supersaturated contributing to form a metastable 
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subproteome highly susceptible to aggregate (207, 208). Moreover, the  amyloid precursor protein 
and ca. 35 and 40% of proteins co-aggregating with amyloid plaques and intracellular 
neurofibrillary tangles, respectively, are also transcriptionally down-regulated in the central nervous 
system of Alzheimer’s disease patients, in an attempt to limit their further aggregation; such 
percentages are only 4 and 10% in aged-matched healthy controls, respectively, and only 10% and 
1-3% of the human proteome is down-regulated in diseased and healthy controls, respectively 
(209). 
 
LOOKING TO THE FUTURE – FROM THEORY TO THERAPY 
The various sections of this review witness the major advances made over the past decade in the 
field of protein aggregation and its links with human disease. It is particularly significant that such 
major progress has been made in defining the fundamental principles that underlie the mechanism 
of self-assembly, as well as the nature and structure of both the oligomeric and fibrillar species in 
many systems, particularly those that are studied in greater detail. The major determinants of 
protein aggregate toxicity also appear to emerge as well as the mechanisms by which protein 
aggregates are detrimental to the cells. 
Considerable progress has also been made in understanding the manner in which our natural 
defences are able to protect us against the effects of protein misfolding and aggregation under 
normal circumstances. It is evident that the inherent properties of natural protein sequences, in 
addition to features of biological environments such as the low protein concentration, high turnover 
and compartmentalisation, can act to increase the kinetic stability of native states of proteins 
cooperating with the proteostasis network. It is also clear that when such protection mechanisms 
become overwhelmed, a range of metastable proteins becomes increasingly vulnerable to 
aggregation, a situation that can lead to a widespread and irretrievable loss of protein homeostasis 
with fatal consequences. 
 In this scenario of increasing knowledge, the rational design of an increasing number of 
therapeutic strategies is a natural outcome. The ability of antibodies to bind not just to unique 
sequences, but also to well defined aggregation states, has lead to considerable efforts to develop 
immunotherapies for amyloid-associated diseases. Knowledge of the principles of protein 
aggregation and its links with disease, including the manner in which our natural protective 
mechanisms are able to be so effective, is generating a robust platform for the rational design of 
small molecules for the prevention or treatment of protein deposition diseases. In the case of 
globular proteins, one strategy is to stabilise the folded state to prevent both unfolding and the 
structural fluctuations that generate native-like states. One outstanding example of a therapeutic 
strategy based on this approach involves an analogue of the substrate thyroxine, called tafamidis, 
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which acts to stabilise the native tetramer of transthyretin and reduce its aggregation propensity and 
is now increasingly widely utilised in the clinic to cure familial amyloid polyneuropathy. 
In cases where the aggregation-prone protein or protein fragment is intrinsically disordered, 
stabilisation of the stable state is more challenging, and many rational design efforts have focused 
on inhibition of the process of aggregation itself. All early attempts to develop ‘aggregation 
inhibitors’, however, failed at one or other stage of clinical trials. Examination of such failures, 
however, indicates that the lack of methods to monitor the aggregation reaction in a reliable 
manner, the lack of knowledge of the specific step(s) affected by the compound in question and to 
intervene early in the disease are contributing factors. More recent efforts are being focussed on 
specific steps in the aggregation reaction by screening compounds in vitro to identify potential 
inhibitors towards therapies for both Alzheimer’s and Parkinson’s disease. 
Another strategy that is still widely explored in spite of previous failures in clinical trials is 
the search of inhibitors of the specific proteases that produce amyloidogenic fragments, such as the 
- and -secretases that produce the N- and C-termini of A fragements. Such a search may involve 
in the future inhibitors of the furin and metalloendopeptidase that produce the N- and C-termini of 
the amyloidogenic fragment of gelsolin and of the enigmatic protease that generates the 
amyloidogenic N-terminal fragments of apoliporotein A-I, among other examples. 
In nonneuropathic amyloidosis the elimination of the source of amyloidogenic proteins, such 
as plasma cell elimination with chemotheraphy in light chain amyloidosis, liver transplant in 
transthyretin amyloidoses, or the maintenance of a low inflammatory response in AA amyloidosis 
to reduce production of the serum amyloid A protein, are effective therapeutic avenues. 
 The list of promising strategies to cure the various protein deposition diseases is difficult to 
summarise exhaustively in one review but in summary there are many different strategies for 
intervention, many of which involve a subtle rebalancing of the multiplicity of states represented in 
Figure 1. In the review we have emphasised our increasing understanding of the molecular origins 
of amyloid-related diseases that is now leading to real progress in the rational development of a 
variety of means of therapeutic intervention, some of which we have outlined briefly in this review.  
In addition, we are optimistic that other approaches will prove viable, such as the stimulation of our 
natural defence mechanisms and the ability to perturb our genetic nature through the continuing 
development of gene therapy or stem cell techniques. As in the treatment of other chronic non-
infectious disorders such as heart disease and cancer, it is likely that success in the prevention and 
treatment of complex neurodegenerative disorders will best be achieved by the availability of a 
range of approaches that can be applied to reduce the risk of the development of the disease and 
also at different stages of its progression and with the ability to be personalised in response to the 
differing genetic make-up of those afflicted by such conditions. We hope that a review in another 
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ten years will be able to report dramatic progress in this regard, and we are optimistic that this hope 
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Table 1 – Peptides or proteins forming extracellular amyloid deposits or intracelullar inclusions with 





Structureb Associated Diseases Type of 
diseasec 
amyloid  peptide (A) 40 or 42d Intrinsically 
disordered 
-  Alzheimer’s disease 




-synuclein (S) e 140 Intrinsically 
disordered 
-  Parkinson’s disease 
-  Parkinson’s disease with dementia 
-  Dementia with Lewy bodies 
-  Multiple system atrophy 
Neuropathic 
Sporadicf 






-  Creutzfeldt-Jacob disease 
-  Fatal insomnia 
-  Gerstmann-Sträussler-Scheinker 
disease 
-  Huntington disease-like 1 
-  spongiform encephalopathy with 
neuropsychiatric features 
-  New variant Creutzfeldt-Jacob 
disease 










-  Pick’s disease 
-  Progressive supranuclear palsy 
-  Corticobasal degeneration 
-  Frontotemporal dementia with 
parkinsonism linked to chr17   
-  Argyrophilic grain disease 
-  Tangle predominant dementia 
-  Guam Parkinson dementia 
complex 
-  frontotemporal lobar degeneration 
-  chronic traumatic encephalopathy 
-  ganglioglioma 
-  meningioangiomatosis 
-  subacute sclerosing  
-  panencephalitis 
-  lead encephalopathy 
-  tuberous sclerosis 
-  Hallervorden-Spatz disease 
-  lipofuscinosis 
Neuropathic 
Sporadicf 




-  Huntington disease Neuropathic 
hereditary 
ABri peptide 34 Intrinsically 
disordered 





ADan peptide 34 Intrinsically 
disordered 
-  Familial Danish dementia Neuropathic 
hereditary 
 Fragments of immunoglobulin 
light chains h  
~100d All-, Ig-like -  light chain amyloidosis Systemic 
Sporadicf 
Fragments of immunoglobulin 
heavy chains h  
~190d All-, Ig-like -  heavy chain amyloidosis  




Full or N-term fragments of serum 








Transthyretin (TTR) 127 All-, 
prealbumin 
like 
-  Senile systemic amyloidosis 
-  Familial amyloidotic 
polyneuropathy 
-  Familial amyloid cardiomyopathy 





2-microglobulin (2-m) 99 All-, IG like -  Dialysis-related amyloidosis 
-  hereditary visceral amyloidosis 
Systemic 
Iatrogenicf 
N-term fragments of 
apolipoprotein A-I (apoAI) 
69-100d Intrinsically 
disordered 
-  ApoAI amyloidosis (many organs) Systemic 
hereditary 
C-term extended apolipoprotein A-
II (apoAII) 




N-term fragments of 
apolipoprotein A-IV (apoAIV) 




Fragments of gelsolin  53 or 71d Intrinsically 
disordered 





Lysozyme (LYS) 130 +, 
lysozyme fold 








N-term truncated cystatin C 110 +, cystatin 
like 
- Hereditary cerebral hemorrhage 
with amyloidosis, Icelandic type 
Systemic 
Hereditary 
islet amyloid polypeptide (IAPP) 37 Intrinsically 
disordered 
-  Type II diabetes 
-  Insulinoma 
Localised 
Sporadic 
Calcitonin 32 Intrinsically 
disordered 




Atrial natriuretic factor (ANF) 28 Intrinsically 
disordered 
-  Atrial amyloidosis Localised 
Sporadic 
N-term fragments of prolactin 
(PRL) 
34 unknown -  Pituitary prolactinoma Localised 
Sporadic 
Insulin (30+21)i All-, insulin 
like 
-  Injection-localized amyloidosis Localised 
iatrogenic 
Medinj 50 Intrinsically 
disordered 
-  Aortic medial amyloidosis Localised 
Sporadic 










associated protein (ODAM) 















133 unknown - Renal amyloidosis Systemic 
sporadic 






- lichen amyloidosus 
- macular amyloidosis 
Localised 
sporadic 




- hypotrichosis simplex of the scalp Localised 
hereditary 
C-term fragments of kerato-
epithelin (ig-h3) 
50-200d Unknown 
- Lattice corneal dystrophy, type 1 
- Lattice corneal dystrophy, type 3A 




Semenogelin-1 (SGI) 439 Unknown - Seminal vesicle amyloidosis Localised 
sporadic 
Proteins S100A8/A9  92/113 All-,  
EF hand-like 




36 Unknown -  Injection-localized amyloidosis Localised 
iatrogenic 
 
a Lengths of the processed forms depositing into the aggregates, not the precursor proteins. 
b Structural class and fold of the native, processed protein/peptide prior to aggregation, according to Structural 
Classification Of Proteins (SCOP). 
c Diseases are classified as (i) neuropathic, systemic or localized (non-neuropathic) and (ii) sporadic, hereditary, 
iatrogenic (following medical treatment) or infectious 
d Fragments of various lengths were reported in ex vivo fibrils 
e Intracellular proteins, unlike the others that are extracellular. 
f Predominantly sporadic, although hereditary forms are documented. 
g Involving both the central nervous system and other organs, thus systemic but also neuropathic 
h Also forming non-amyloid deposits in light-chain or heavy-chain deposition disease (LCCD and HCDD). 
i Lengths of the A and B chains linked by a disulphide bridge 











Table 2 – Peptides or proteins forming intracellular or extracellular non-amyloid deposits in human 
diseasesa 
Peptide/protein name No. of 
residuesb 
Structurec Associated Diseases Type of 
diseased 
Neurogenic locus notch 
homolog protein 3 
(Notch 3) ectodomain 
1589 Unknown -  Cerebral autosomal dominant 





Immunoglobulin  heavy 
chainse 
~ 345 All-, 
Ig-like 






~ 215 All-,  
Ig-like 
-  Light chain deposition disease 
-  myeloma cast nephropathy 
-  Fanconi syndrome 
(all are renal) 
Systemic 
Sporadic 
Fibronectin (FN) 2355 All-,  
FnI-like domain 




protein 43 (TDP-43) 
414 Unknown -  Frontotemporal lobar degeneration 
with ubiquitin-positive inclusions 














~ 2700g All-, Ig-like -  IgA nephropathy (Berger disease) 





392 +,  
PLP-dependent 
transferase-like 




~ 6750g All-, Ig-like -  Multiple myeloma / plasmacytoma 





~ 1350g All-, Ig-like -  Multiple myeloma / plasmacytoma 





glycoprotein (THP)  
590 unknown - Medullary cystic kidney disease 2 
- Familial juvenile hyperuricemic 
nephropathy 
- Glomerulocystic kidney disease 
Localised 
hereditary 





- Spinocerebellar ataxia 1 neuropathic 
hereditary 
Hemoglobin 574g All-,  
globin-like 
- Sickle cell anemia 
- Heinz body anemia 
- Inclusion body -thalassemia  
Localised 
hereditary 
1-antitrypsinh  394  + , serpin - 1-antitrypsin deficiency Localised 
hereditary 
a The peptides and proteins listed in the table include cases reported to form either extracellular or intracellular 
deposits with evidence for non-amyloid structure. 
b Data refer to the processed polypeptide chains that deposit into aggregates, not to the precursor proteins. 
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c Structural class and fold of the native, processed protein/peptide prior to aggregation, according to Structural 
Classification Of Proteins (SCOP). 
d Diseases are classified as (i) neuropathic, systemic or localized (non-neuropathic) and (ii) sporadic, hereditary 
e This protein has also been reported to form amyloid deposits in AH and AHL amyloidosis 
f This protein has also been reported to form amyloid deposits in AL and AHL amyloidosis 
g Calculated considering all subunits forming the protein 




Table 3 – Peptides or proteins forming amyloid-like fibrils with physiological roles in humansa 
Peptide/protein name No. of 
residuesb 
Structurec Physiological role 
Intralumenal domain of 
melanocyte protein 
PMEL 
442 Unknown (NTR, 25-214),      
all-, Ig-like (PKD, 215-297), 
unknown (RTD, 315-444) 
To form, inside melanosomes, fibrious 
striations upon which melanin granules form  
Various peptide 
hormones in pituitary 
secretory granules 





protein kinase 1/3 
(RIP1/RIP3) 
671/518 +, kinase-like (1-324), 
intrinsic. disordered (325-end) 
To mediate the TNF-induced programmed 
cell necrosis 
Fragments of prostatic 
acid phosphatase and 
semenogelins 
 
36-63 Intrinsically disordered Unknown for humans, exploited by the HIV 
virus for infection 
a The peptides and proteins listed in the table include cases reported to form functional amyloid in humans. The 
table does not report fragments of prostatic acid phosphatase and semenogelins recently detected in amyloid forms 
in the human semen as its functional role in humans remains to be established. 
b Data refer to the processed polypeptide chains that deposit into aggregates, not to the precursor proteins. 
c Structural class and fold of the native, processed protein/peptide prior to aggregation, according to Structural 






Figure 1. Schematic illustration of the multiplicity of conformational states that can be adopted by 
a polypeptide chain following its biosynthesis, and the possible transitions between the different 
states. All of these conformational states and their interconversions are carefully regulated in the 
biological environment by means of the proteostasis network. Protein aggregation can result in the 
formation of amyloid fibrils (centre), native-like deposits (right) or amorphous deposits (left), all of 
which are associated with pathological states when they form in a non-controlled manner. 
 
Figure 2. Schematic representation of the different mechanisms of action by which mutations 
associated with hereditary amyloid diseases can cause protein aggregation and its associated 
pathological states. Each of the 10 numbered boxes in the figure shows a mechanism of action, 
along with the names of the mutated peptides/proteins for which the mechanism is described in the 
literature. 
 
Figure 3. Three-dimensional structures and structural models of amyloid fibrils from different sources. (a) 
Two polymorphic structural models of A40 protofilaments viewed down the long axis of the fibril, shown as 
a ribbon (left) and stick (right) models. Each layer consists of two (top) or three (bottom) A40 molecules. -
strands encompassing residues 10-22 and 30-40 are depicted in red and blue, respectively (left). Reproduced 
with permission from ref. 75 (top) and ref. 65 (bottom). (b) Atomic structure of the microcrystals assembled 
from the LVEALYL peptide. Each -strand is a peptide molecule viewed along (top) and down (bottom) the 
long axis of the fibril. Reproduced with permission from ref. 210. (c) Left-handed -solenoid structure of the 
fibril of the HET-s prion domain (residues 218-289) from P. anserina viewed along (top) and down (bottom) 
the long axis of the fibril. Different colours indicate different molecules. Each molecule contributes to two 
windings of the -solenoid and 8 -strands termed 1a, 1b, 2a, etc. Reproduced with permission from ref. 
66. (d) Structural model of native-like protofilaments from transthyretin, having unfolded C and D strands, 
and native-like AGH and BEF sheets that assemble to form two antiparallel -sheets and the cross- core of 
the protofilament. A section of the protofilament is shown enlarged. Readapted with permission from ref. 
101. In all panels the arrow represents the axis of the fibril. 
 
Figure 4. Aggregation propensity profiles for A (a), -synuclein (b), IAPP (c) and the K19 fragment of tau 
(d), all determined according to ref. 122. In each panel, the aggregation propensity profile (solid blue line) is 
compared with the regions of the sequence found experimentally to form the -sheet core of the fibrils 
(horizontal bars) according to the references and methods indicated in the panel. 
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Figure 5. (a) Possible mechanisms of nucleus formation starting from a globular or intrinsically disordered 
protein. The vertical boxes refer to different stages of the amyloid fibril formation process, whereas the 
horizontal lines refer to different models of aggregation, i.e. the nucleated polymerisation (red arrows), the 
nucleated conformational conversion (blue arrows), and the native-like aggregation (green arrows). The 
vertical box on the right refer to secondary processes, such as secondary nucleation (top) and fibril 
fragmentation (bottom). (b) Schematic representation of the structural rearrangements occurring during 
oligomer formation. Amyloidogenic segments are coloured in green. As aggregation proceeds (left to right) a 









































































folded protein bound to its
target molecule
(i.e. protein, lipids, etc.)
folded protein 
bound to its 
ligand (i.e. Ca2+)
Mutations causing alternative splicing of pre-mRNA to form an mRNA 
coding for a more amyloidogenic protein: i.e. mutations of τ2
Mutations causing premature stop of translation, resulting into unfolded 
fragments: i.e. mutations of CDSN, PrP3
Mutations causing late stop of translation, resulting into additional amyloidogenic 
unfolded fragments: i.e. mutations of Abri, ADan, apoAII4
Mutations destabilising the folded state, causing higher concentrations of amyloidogenic 
partly folded states: i.e. TTR, LYS, cystatin C, PrP, β2m7
Mutations destabilising the folded state, resulting into proteolytic cleavage and 
formation of unfolded amyloidogenic fragments: i.e. mutations of apoAI8
Mutations decreasing the folded state affinity for its ligand, causing proteolytic 
cleavage and formation of unfolded amyloidogenic fragments: i.e. gelsolin9
Mutations causing detachment from partner 
protein/molecule: i.e. τ, apoAI10
Mutations changing prot. cleavage, forming 
more amyloidog. fragments: i.e. Aβ  5
Mutations increasing intrinsic 
aggregation rate: i.e. Aβ, τ, PrP, ApoAI, 
αs
6
Gene duplication/triplication or expansion, causing a 
higher concentration of protein or expanded 
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